Skip to main content

Lexicon Licenses Gene Target Technology to Immunex

NEW YORK, Feb 6 – Lexicon said Tuesday it has licensed its gene targeting technology to Immunex, bringing to 14 the number of its sublicensees.

Under the terms of the deal, Lexicon will receive annual license fees, technology usage frees for any model Immunex develops using the technology, as well as milestone payments for future discoveries.

Exact figures were not disclosed.

Lexicon of The Woodlands, Tex., determines gene function using large-scale knockout mouse technology.

It has collaborations and alliances with companies such as Abgenix, Bristol-Myers Squibb, American Home Producs, and DuPont.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.